Role of macrophages in Wallerian degeneration and axonal regeneration after peripheral nerve injury Peiwen ChenXianhua PiaoPaolo Bonaldo Review 29 September 2015 Pages: 605 - 618
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies Jens WagnerSybille KraussMartin Fuhrmann Original Paper Open access 06 October 2015 Pages: 619 - 631
PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia Helois RadfordJulie A. MorenoGiovanna R. Mallucci Original Paper Open access 08 October 2015 Pages: 633 - 642
Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43 Adam K. WalkerKrista J. SpillerVirginia M.-Y. Lee Original Paper 22 July 2015 Pages: 643 - 660
Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS Yazi D. KeAnnika van HummelLars M. Ittner Original Paper 05 October 2015 Pages: 661 - 678
Rab1-dependent ER–Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS Kai Y. SooMark HalloranJulie D. Atkin Original Paper 23 August 2015 Pages: 679 - 697
Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies James P. FullerJeffrey B. StavenhagenJessica L. Teeling Original Paper Open access 03 October 2015 Pages: 699 - 711
Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models Yvonne BouterJose Socrates Lopez NoguerolaThomas A. Bayer Original Paper 14 October 2015 Pages: 713 - 729
PDCD10 (CCM3) regulates brain endothelial barrier integrity in cerebral cavernous malformation type 3: role of CCM3-ERK1/2-cortactin cross-talk Svetlana M. StamatovicNikola SladojevicAnuska V. Andjelkovic Original Paper 18 September 2015 Pages: 731 - 750